Compare Recursion Pharmaceuticals Inc (RXRX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Virgin Galactic Holdings, Inc. trades at $2.98 (market cap $474.50M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.9× Virgin Galactic Holdings, Inc.'s market cap. Which is the better fit depends on your goals.
| RXRX | SPCE | |
|---|---|---|
Market Cap | $1.86B | $474.50M |
Sector | Health | Industrials |
52-Week High | $6.79 | $7.52 |
52-Week Low | $2.84 | $2.17 |
Enterprise Value | $1.38B | $438.48M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Virgin Galactic (SPCE) trades at $3.13, up 2.96% with a bullish technical outlook from moving averages. The company continues to report significant losses with negative profit margins and cash flow, though recent quarters have shown earnings beats. Management targets positive cash flow by 2027, but commercial spaceflight delays to February 2027 create execution risk. Analyst sentiment is divided with 29% buy, 41% hold, and 29% sell ratings.
SPCE represents a high-risk, speculative opportunity in the emerging space tourism sector. The path to profitability remains distant with substantial cash burn, though strong ticket demand provides potential upside if execution improves. Key risks include ongoing dilution, high short interest, and the capital-intensive nature of space operations. Investors should weigh the long-term potential against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
